Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300357 Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.

Trading 04-23 14:04:57

26.01

-0.63

-2.36%

High26.61	Low26.00	Vol6.98M
Open26.48	D1 Closing26.64	Amplitude2.29%
Mkt Cap13.63B	Tradable Cap12.59B	Total Shares524.00M
T/O183.00M	T/O Rate1.44%	Tradable Shares484.00M
P/B5.29	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.","latestPrice":26.01,"timestamp":1776924297000,"preClose":26.64,"halted":0,"volume":6979784,"delay":0,"changeRate":-0.0236,"floatShares":484000000,"shares":524000000,"eps":0.7457,"marketStatus":"Trading","change":-0.63,"latestTime":"04-23 14:04:57","open":26.48,"high":26.61,"low":26,"amount":183000000,"amplitude":0.0229,"askPrice":26.01,"askSize":33,"bidPrice":26,"bidSize":368,"shortable":0,"etf":0,"ttmEps":0.7457,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776927600000},"marketStatusCode":2,"adr":0,"adjPreClose":26.64,"symbolType":"stock","openAndCloseTimeList":[[1776907800000,1776915000000],[1776920400000,1776927600000]],"highLimit":29.3,"lowLimit":23.98,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":5.29,"roa":"--","peRate":34.879979,"roe":"13.8%","epsLYR":0.607,"committee":0.697868,"marketValue":13618000000,"turnoverRate":0.0144,"status":1,"floatMarketCap":12591000000},"requestUrl":"/m/hq/s/300357/wiki","defaultTab":"wiki","newsList":[{"id":"2626188881","title":"Zhejiang Wolwo Bio-Pharmaceutical Enrolls First Subject in Phase 2 Trial for Allergic Rhinitis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2626188881","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626188881?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:31","pubTimestamp":1775727096,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical  enrolled the first subject of its phase 2 clinical trial for its house dust mite film, according to a Wednesday after-hours filing with the Shenzhen bourse.The treatment is indicated for allergic rhinitis patients affected by dust mites, the filing said.Shares finished nearly 1% on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131864662","title":"Wolwo Bio-Pharmaceutical Advances Dust Mite Film Agent to Phase II Clinical Trial Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1131864662","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131864662?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:30","pubTimestamp":1775637027,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) has announced that the first participant has been enrolled in a Phase II clinical trial for its \"Dust Mite Film Agent.\" The trial, which is...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618312181","title":"Wolwo Bio-Pharmaceutical Unit Applies for Stem Cell Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2618312181","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618312181?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316858,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical  unit Zhejiang Stem Cell obtained acceptance from China's drug regulator for the clinical trial application for its human umbilical cord mesenchymal Stem cells type II injection.The stem cell therapy targets sepsis and septic shock, according to a Wednesday filing with the Shenzhen bourse.Shares of the drug company closed 1% higher Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162992877","title":"Zhejiang Wolwo Bio-Pharmaceutical's Indirect Subsidiary Receives Acceptance for Clinical Trial Application of Novel Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1162992877","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162992877?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:56","pubTimestamp":1773219396,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) announced that its indirect controlling subsidiary, Zhejiang Wolwo Stem Cell Technology Co., Ltd., has received an acceptance notice from the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164878873","title":"Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Terminates Aspergillus Fumigatus Skin Prick Test Solution R&D Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1164878873","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164878873?lang=en_us&edition=fundamental","pubTime":"2025-11-14 16:48","pubTimestamp":1763110104,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) announced that after careful evaluation by the management team, the company has decided to terminate the R&D project for Aspergillus Fumigatus...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176592717","title":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) Reports Q3 Results with Net Profit of 345 Million Yuan, Up 26.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176592717","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176592717?lang=en_us&edition=fundamental","pubTime":"2025-10-23 19:44","pubTimestamp":1761219855,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has released its Q3 report for 2025, indicating that the company achieved a revenue of 853 million yuan in the first three quarters, marking a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","stockEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.1303},{"period":"3month","weight":-0.1066},{"period":"6month","weight":-0.1879},{"period":"1year","weight":0.34},{"period":"ytd","weight":-0.0572}],"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","perCapita":"14927股","boardName":"医药制造业","registeredCapital":"52358万元","compareEarnings":[{"period":"1week","weight":0.0196},{"period":"1month","weight":0.0768},{"period":"3month","weight":-0.004},{"period":"6month","weight":0.0395},{"period":"1year","weight":0.2444},{"period":"ytd","weight":0.0346}],"survey":"　　浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂以及粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。","serverTime":1776924300501,"listedPrice":20.05,"stockholders":"32427人(较上一季度减少6.22%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.,300357,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票老虎,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票老虎国际,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.行情,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票行情,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股价,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股市,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票价格,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票交易,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票购买,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction